Metabolic & Weight Management Peptides
FDA-approved and investigational peptides for metabolic disorders, weight management, and obesity research. Includes GLP-1 receptor agonists and incretin-based therapies.
This category includes some of the most clinically validated peptides in existence. GLP-1 receptor agonists like semaglutide and tirzepatide represent a paradigm shift in obesity and type 2 diabetes treatment, with large Phase 3 programs and FDA approval.
Semaglutide (GLP-1 Receptor Agonist)
Evidence Tier: FDA-Approved — Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy). One of the most extensively studied peptides in clinical medicine.
Tirzepatide (Dual GIP/GLP-1 Agonist)
Evidence Tier: FDA-Approved — Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Developed by Eli Lilly, it represents the next generation of incretin-based therapies.
AOD-9604 (Anti-Obesity Drug Fragment 176-191)
Evidence Tier: Phase 1-2 — AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that retains fat-metabolizing properties without the growth-promoting effects of full GH.